881
Based on prior data suggesting that scheduling alterations of platinum would increase activity, the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin in PROC patients.
 ( potential therapeutic event: assess ,  PROC patients: Subject, potential therapeutic benefit: Effect, phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin: Treatment, phenoxodiol: Treatment.Drug, carboplatin: Treatment.Drug, PROC: Treatment.Disorder, weekly: Treatment.Freq, carboplatin: Combination.Drug, phenoxodiol: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: assess ,  PROC patients: Subject, potential therapeutic benefit: Effect, phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin: Treatment, phenoxodiol: Treatment.Drug, carboplatin: Treatment.Drug, PROC: Treatment.Disorder, weekly: Treatment.Freq, carboplatin: Combination.Drug, phenoxodiol: Combination.Drug) 